Article Text

Download PDFPDF

5PSQ-099 Adequacy of sotrovimab prescription in SARS-CoV-2 infection in a university hospital
  1. T Blanco Espeso,
  2. M Florido Francisco,
  3. R Serrano Giménez,
  4. M Rodriguez Jorge
  1. Hospital Juan Ramón Jiménez, Hospital Pharmacy, Huelva, Spain


Background and Importance The Spanish Medicines and Health Products Agency (AEMPS) has developed criteria to adapt the prescription of sotrovimab1, due to the pandemic situation and the limited drug stock.

Aim and Objectives To describe the patients´ population on treatment with sotrovimab and to assess the adequacy of this prescription according to the criteria established by the AEMPS.

Material and Methods Retrospective observational study analysing all sotrovimab prescriptions in patients with SARS-CoV-2 infection from 01/25/2022 to 08/31/2022.

Demographic variables and data required by the AEMPS for sotrovimab prescription were collected: Omicron variant infection, SARS-CoV-2 vaccination status, serology [anti-S antibody<260 BAU (binding antibody units)/mL]. Also, patients had to belong to one of the following groups:

  • Group 1: Immunocompromised, regardless of vaccination status.

  • Group 2: >80 years unvaccinated.

  • Group 3: >65 years (regardless of vaccination status) and ≥1 risk factor for progression.

Prescriptions for sotrovimab were collected and analysed to determine whether they met the criteria and whether they were accepted. Data collected from electronic medical records and processed using Excel2019®.

Results Fifty patients were included, 62% male; median age 69 years (IQR=60-76). 100% had the Omicron variant. Vaccination status: 84% complete, 6% incomplete and 10% unvaccinated. Serology: 96% (<260 BAU/mL) and 4% (>260 BAU/ml). 92% belonged to group 1 (39% solid organ transplantation, 29% active myelotoxic chemotherapy, 13% non-cytotoxic onco-haematological treatments with neutropenia/lymphopenia, 13% treatment with biological immunomodulators, 2% Down’s syndrome, 2% haematopoietic stem cell transplantation or CAR-T, 2% HIV infection (with ≤200 cells/mL). Two per cent belonged to group 2. The remaining patients (6%) did not belong to any group. Ten per cent of the applications did not meet the criteria: four of them were not accepted (patients did not belong to any risk group); one was accepted, although it was a well-controlled HIV.

Conclusion and Relevance The main profile of patients treated with sotrovimab is men with solid organ transplantation, vaccinated and with negative immunity to SARS-CoV-2. Although the appropriateness of the prescription is high, it is necessary to continue protocolising the use of this drug to ensure its rational use.

References and/or Acknowledgements 1. 1.

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.